Sunesis Pharmaceuticals Announces Withdrawal of European Marketing Authorization Application (MAA) for Vosaroxin as a Treatment for Relapsed/Refractory AML

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ABBV
3. SPY
4. META
5. MU
6. ACN
7. NVDA
8. BLZE
9. IBM
10. PRIM

Go back to Sunesis Pharmaceuticals Announces Withdrawal of European Marketing Authorization Application (MAA) for Vosaroxin as a Treatment for Relapsed/Refractory AML

Sunesis Pharmaceuticals Inc. (SNSS) PT Lowered to $3 at Cantor Fitzgerald Following MAA Withdrawl

May 2, 2017 6:53 AM EDT

Cantor Fitzgerald lowered its price target on Sunesis Pharmaceuticals Inc. (NASDAQ: SNSS) to $3.00 (from $5.00) while maintaining a Neutral rating. SNSS has withdrawn its MAA in the EU for vosaroxin, essentially ending the company's chances for marketing approval without additional clinical... More